Galunisertib, another TGF-β receptor 1 inhibitor, prevents the TGF-β-induced fibroblast activation in ovarian cancer and, as a consequence, reduces migration and invasion of the cancer cells [127]. This evidence concerns the gene TGFB1 and cancer.